Ligand discovers, develops and markets new drugs for critical unmet medical needs in the areas of cancer, pain, skin diseases, hormone related diseases, osteoporosis, metabolic disorders, cardiovascular and inflammatory diseases. Ligand s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology related to intracellular receptors.
Quote | Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt (OTCMKTS:LGNZZ)
Last: | $0.109 |
---|---|
Change Percent: | 8.26% |
Open: | $0.1 |
Close: | $0.109 |
High: | $0.109 |
Low: | $0.1 |
Volume: | 1,082 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt (OTCMKTS:LGNZZ)
2024-04-25 10:05:00 ET Summary Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP returned 6.0% for the First Quarter of 2024. The Fund has annualized returns of 10.0% since inception, compa...
2023-11-08 22:22:05 ET Ligand Pharmaceuticals Inc. (LGND) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Simon Latimer - Head-Investor Relations Todd Davis - Chief Executive Officer Matthew Korenberg - President and Chief Operat...
Message Board Posts | Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt (OTCMKTS:LGNZZ)
Subject | By | Source | When |
---|---|---|---|
This one didn't get audited ? | $theDDmessiah | investorshub | 04/05/2020 2:18:52 AM |
Pretty quiet over here | Moose Cat | investorshub | 04/04/2020 4:48:44 AM |
Interesting. Another burst of volume today | Garyst | investorshub | 06/08/2018 4:05:23 AM |
Very interesting I Have a lotto here now | Kicko | investorshub | 06/07/2018 7:22:38 PM |
No idea, but buying has been steady for | buxmaker | investorshub | 06/07/2018 7:22:02 PM |